about
Stimuli-Responsive Polymeric Systems for Controlled Protein and Peptide Delivery: Future Implications for Ocular DeliveryIntracellular targeting with engineered proteinsRecent Developments in Active Tumor Targeted Multifunctional Nanoparticles for Combination Chemotherapy in Cancer Treatment and ImagingProfile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosisLong-term delivery of protein therapeuticsOphthalmic Uses of a Thiol-Modified Hyaluronan-Based HydrogelNovel Therapy to Treat Corneal Epithelial Defects: A Hypothesis with Growth HormoneSerendipitous alkylation of a Plk1 ligand uncovers a new binding channelLiposomal Antioxidants for Protection against Oxidant-Induced DamageBoronic Acid for the Traceless Delivery of Proteins into CellsInduction of Cancer Cell Death by Hyaluronic Acid-Mediated Uptake of Cytochrome CBrain delivery of proteins via their fatty acid and block copolymer modificationsThe effect of protein structure on their controlled release from an injectable peptide hydrogel.Drug delivery systems, CNS protection, and the blood brain barrierInternalization by multiple endocytic pathways and lysosomal processing impact maspin-based therapeutics.High-throughput thermal stability analysis of a monoclonal antibody by attenuated total reflection FT-IR spectroscopic imaging.Smart Release Nano-formulation of Cytochrome C and Hyaluronic Acid Induces Apoptosis in Cancer Cells.Recent application of analytical methods to phase I and phase II drugs development: a review.Next generation delivery system for proteins and genes of therapeutic purpose: why and how?Agile delivery of protein therapeutics to CNSNANOMATERIALS FOR PROTEIN MEDIATED THERAPY AND DELIVERY.A solvent-free thermosponge nanoparticle platform for efficient delivery of labile proteins.Functional human antibody CDR fusions as long-acting therapeutic endocrine agonists.Stimuli-responsive nanomaterials for therapeutic protein delivery.Side-by-Side Comparison of Commonly Used Biomolecules That Differ in Size and Affinity on Tumor Uptake and Internalization.Combinatorial library strategies for synthesis of cationic lipid-like nanoparticles and their potential medical applications.The influence of artificially introduced N-glycosylation sites on the in vitro activity of Xenopus laevis erythropoietin.Phosphatidylinositol induces fluid phase formation and packing defects in phosphatidylcholine model membranesPEGylation of a factor VIII-phosphatidylinositol complex: pharmacokinetics and immunogenicity in hemophilia A mice.Shape Control in Engineering of Polymeric Nanoparticles for Therapeutic Delivery.Site-selective glycosylation of hemoglobin with variable molecular weight oligosaccharides: potential alternative to PEGylation.Polymeric conjugates for drug deliveryCan formulation and drug delivery reduce attrition during drug discovery and development-review of feasibility, benefits and challenges.A Simple and Rapid Method for Preparing a Cell-Free Bacterial Lysate for Protein Synthesis.New treatments in hemophilia: insights for the clinician.A Drug Delivery System for Administration of Anti-TNF-α Antibody.Reactive Self-Assembly of Polymers and Proteins to Reversibly Silence a Killer Protein.A cell-penetrating peptide suppresses the hypoxia inducible factor-1 function by binding to the helix-loop-helix domain of the aryl hydrocarbon receptor nuclear translocatorAllometry of factor VIII and informed scaling of next-generation therapeutic proteins.PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update.
P2860
Q26740005-7859D004-DD22-419A-8C33-D60233835D13Q26740106-43A6725F-77A8-407C-AAF6-3EAD6D879ECEQ26778234-C261280C-F9C1-498C-ACF6-F922D89EDA32Q26852672-C196C2A8-9F90-4F78-9330-83CC8CC57656Q26860505-4DE578C3-1F2C-4859-B83E-9AF304FAF5E0Q27014963-A062529A-CDDB-4BAE-9346-3F127ECA495FQ27021208-9907BE3B-C0B7-416A-93AD-FAB93757D039Q27670838-24DCD332-6FF9-49C6-B121-4E7DD23C0B74Q28391211-2C130D0E-00E2-4AF5-A1B6-52960D38AE65Q28828230-0452CF4C-D4B5-4E2E-B6BB-60E16241376CQ28834397-3894AD2C-CCB9-4C54-87F1-E8B6A8BB9CD3Q30354932-1771C0E7-E618-48B0-A07D-F141BDDD15EEQ30394951-34D12D57-F588-44FC-B129-AC0E1B1236AFQ30432845-9E226BA8-A153-4DB4-A805-70F76AE5801FQ30594122-BA4367B9-89B2-4399-8103-06B412915CC3Q30596814-EAEA239C-7B1E-4B70-97BF-23E290AEF142Q33894458-FBA8533D-B666-46C0-B3B7-E73D132868C7Q33997398-D328B030-96A1-48E7-9C3A-382FC68CF6F5Q34003800-7E050D13-B6BA-49FA-8984-825F1E0B3596Q34079647-C31665F2-5F2D-4335-9C1C-3B6152C62360Q34534023-C051F9C6-8281-4395-8CCA-140E293EEA3DQ34579897-3460A60E-7675-4B76-B7B9-ABC1307BE362Q35062566-CC7AA162-784D-4532-9342-27877E738A9AQ35088244-A2896C78-A146-473D-96B2-AD10F771AE6DQ35527009-ECCDAC46-7F5E-4564-929B-5F79DB225927Q35568750-6AD47F9B-F086-4ACE-823F-56DA773AC9E0Q35610754-D4EAEB1E-0809-4518-926F-35EE54D2EA1DQ35645401-88D39D61-DD45-4ACC-A798-2F1EBAB88207Q35793113-E2502859-4A4B-4B7C-845B-CEAA6C341CB1Q35801327-207324BD-EF52-4DFD-90C3-8281DACE3189Q35963914-1C504B3A-56F6-49EC-B80C-CE303062FA93Q36029175-F1879A21-3EFB-4571-B81C-C292143769F1Q36111924-A23D1C8E-BFE1-494D-A648-E964789B816DQ36170839-20846718-8B6C-4542-8A07-966EE358DA45Q36612681-B03AFA88-3619-4A56-B97E-D7AB0680DF2BQ36683809-73D2B7AE-45E3-4727-994A-7C091FE7F644Q36816995-6E124604-6DFE-442F-AFB7-98569335891FQ36865718-368CFDFD-523A-4A51-BE92-5EE81809CDA0Q36912731-8521B21A-AFA5-4451-8167-C99E466C08D7Q36940229-E4903362-009A-4061-AC2C-B043AF6107E2
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Delivery of therapeutic proteins.
@en
Delivery of therapeutic proteins.
@nl
type
label
Delivery of therapeutic proteins.
@en
Delivery of therapeutic proteins.
@nl
prefLabel
Delivery of therapeutic proteins.
@en
Delivery of therapeutic proteins.
@nl
P2093
P2860
P356
P1476
Delivery of therapeutic proteins.
@en
P2093
Dipak S Pisal
Matthew P Kosloski
Sathy V Balu-Iyer
P2860
P304
P356
10.1002/JPS.22054
P407
P577
2010-06-01T00:00:00Z